Adverum Biotechnologies (ADVM) Price & Analysis

Compare

631 Followers

ADVM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.78 - $8.56

Previous CloseN/A

Volume79.70K

Average Volume (3M)107.33K

Market Cap

$66.31M

Enterprise Value$93.00M

Total Cash (Recent Filing)$44.40M

Total Debt (Recent Filing)$92.22M

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Nov 06, 2025

EPS Estimate

-1.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.34

Shares Outstanding20,984,161

10 Day Avg. Volume90,967

30 Day Avg. Volume107,334

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.40

Enterprise Value/Revenue93.00

Enterprise Value/Gross Profit-7.91

Enterprise Value/Ebitda-0.58

Forecast

1Y Price Target

$15.00

Price Target Upside393.42% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe ongoing Phase 3 ARTEMIS trial for lead gene therapy candidate Ixo-vec in wet AMD patients has exceeded enrollment expectations.

Investor ConfidenceThe company announced a $10M private placement with Frazier Life Sciences, notably one of the company’s largest investors, showing confidence in the therapeutic potential of Ixo-vec gene therapy.

Bears Say

Financial ChallengesGiven very limited cash and the need for a second pivotal P3 study for ixo-vec, a near-term announcement on meaningful financing or a significant partnership is critical.

Financing OverhangThere is a financing overhang with cash and equivalents expected to fund operations into 4Q25, particularly in an investment environment that underappreciates novel gene therapy treatments.

Adverum Biotechnologies News

Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)

“We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust...

16d ago

ADVM

Adverum Biotechnologies sees cash runway into 4Q25

Cash, cash equivalents and short-term investments were $44.4 million as of June 30, 2025, compared to $125.7 million...

16d ago

ADVM

Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed

Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Adverum Biotechnologies and keeping the price target...

15d ago

ADVM

Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development

Adverum Biotechnologies ( ($ADVM) ) has released its Q2 earnings. Here is a breakdown of the information Adverum...

16d ago

ADVM

Adverum Biotechnologies price target lowered to $12 from $16 at Mizuho

Mizuho lowered the firm’s price target on Adverum Biotechnologies (ADVM) to $12 from $16 and keeps an Outperform...

2M ago

ADVM

Adverum Biotechnologies Holds Annual Meeting with Key Votes

The latest announcement is out from Adverum Biotechnologies ( ($ADVM) ). On June 17, 2025, Adverum Biotechnologies held...

2M ago

ADVM

Adverum Biotechnologies Reports Q1 2025 Financial Results

Adverum Biotechnologies ( ($ADVM) ) has released its Q1 earnings. Here is a breakdown of the information Adverum...

3M ago

ADVM

Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec’s Advancements in Wet AMD Treatment

TD Cowen analyst Joseph Thome has maintained their bullish stance on ADVM stock, giving a Buy rating today....

4M ago

ADVM

Adverum Biotechnologies price target lowered to $4 from $5 at RBC Capital

RBC Capital lowered the firm’s price target on Adverum Biotechnologies (ADVM) to $4 from $5 and keeps a...

4M ago

ADVM

Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)

Cash, cash equivalents and short-term investmentswere $83.1M as of March 31, compared to $125.7M as of December 31,...

4M ago

ADVM

Adverum Biotechnologies: Promising Gene Therapy Developments and Financial Stability Justify Buy Rating

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ADVM stock, giving a Buy rating yesterday....

4M ago

ADVM

Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress

Adverum Biotechnologies ( ($ADVM) ) has released its Q4 earnings. Here is a breakdown of the information Adverum...

4M ago

ADVM

Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)

“We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a...

5M ago

ADVM

Adverum Biotechnologies sees cash runway into 2H25

Cash, cash equivalents and short-term investmentswere $125.7 million as of December 31, 2024, compared to $153.2 million as...

5M ago

ADVM

ADVM FAQ

What was Adverum Biotechnologies’s price range in the past 12 months?

Adverum Biotechnologies lowest stock price was $1.78 and its highest was $8.56 in the past 12 months.

What is Adverum Biotechnologies’s market cap?

Adverum Biotechnologies’s market cap is $66.31M.

When is Adverum Biotechnologies’s upcoming earnings report date?

Adverum Biotechnologies’s upcoming earnings report date is Nov 06, 2025 which is in 70 days.

How were Adverum Biotechnologies’s earnings last quarter?

Adverum Biotechnologies released its earnings results on Aug 12, 2025. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$2.247 by -$0.093.

Is Adverum Biotechnologies overvalued?

According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adverum Biotechnologies pay dividends?

Adverum Biotechnologies does not currently pay dividends.

What is Adverum Biotechnologies’s EPS estimate?

Adverum Biotechnologies’s EPS estimate is -1.68.

How many shares outstanding does Adverum Biotechnologies have?

Adverum Biotechnologies has 20,984,161 shares outstanding.

What happened to Adverum Biotechnologies’s price movement after its last earnings report?

Adverum Biotechnologies reported an EPS of -$2.34 in its last earnings report, missing expectations of -$2.247. Following the earnings report the stock price went up 10.268%.

Which hedge fund is a major shareholder of Adverum Biotechnologies?

Currently, no hedge funds are holding shares in ADVM

Adverum Biotechnologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

-222.28%

Trailing 12-Months

Asset Growth

-62.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Adverum Biotechnologies

Adverum Biotechnologies (ADVM) is a clinical-stage gene therapy company focused on developing innovative treatments for eye diseases and other serious conditions. The company utilizes its proprietary AAV (adeno-associated virus) technology platform to deliver therapeutic genes directly into targeted tissues, with the goal of providing long-lasting and potentially curative therapies. Adverum's core product candidates include therapies for wet age-related macular degeneration (AMD) and other ocular diseases, aiming to transform the treatment landscape for patients with significant unmet medical needs.

Adverum Biotechnologies (ADVM) Earnings & Revenues

Historic Earnings Reports

ADVM Stock 12 Month Forecast

Average Price Target

$15.00

▲(393.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.32,4.449230769230769,6.5784615384615375,8.707692307692307,10.836923076923076,12.966153846153846,15.095384615384614,17.224615384615383,19.353846153846153,21.483076923076922,23.61230769230769,25.74153846153846,27.870769230769227,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.32,3.295384615384615,4.270769230769231,5.246153846153846,6.2215384615384615,7.196923076923078,8.172307692307692,9.147692307692308,10.123076923076923,11.098461538461539,12.073846153846155,13.04923076923077,14.024615384615386,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.32,2.3723076923076922,2.4246153846153846,2.476923076923077,2.529230769230769,2.5815384615384613,2.6338461538461537,2.686153846153846,2.7384615384615385,2.790769230769231,2.8430769230769233,2.8953846153846152,2.9476923076923076,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.92,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >